Biocon

Mylan and Biocon to present phase-III trastuzumab biosimilar data at ASCO annual meeting

HERITAGE study shows comparable efficacy, safety and immunogenicity to branded trastuzumab in HER2-positive metastatic breast cancer patients

Biocon shares hit 52-week high, here is why

Biocon shares surged after global pharma major Mylan Inc, and the Indian pharma company confirmed the efficacy and safety of MYL-1401O, a proposed biosimilar trastuzumab co-developed by the firms, in comparison to Roche's bra

Biocon shares hit 52-week high, here is why

Mylan, Biocon confirm efficacy of trastuzumab biosimilar

Global pharma major Mylan Inc, and Biocon have confirmed the efficacy and safety of MYL-1401O, a proposed biosimilar trastuzumab co-developed by the firms...

Mylan, Biocon confirm efficacy of trastuzumab biosimilar

Biocon to invest Rs 1,060 crores in Bengaluru plant

The facility is expected to generate at least 750 jobs immediately

Delhi HC refrains from staying single judge interim order over breast cancer drug by Biocon and Mylan

The division bench of the high court, however, said the drug-makers may continue to sell their products under the brand names

Maruti Suzuki, HCL Tech, Yes Bank among 8 stocks that trended in Thursday’s trade

Maruti Suzuki shares closed 2.94 per cent down at Rs 3748.45 after Japense yen soared almost 3 per cent against the dollar and euro as the Bank of Japan opted out of any further moves to ease policy.

Maruti Suzuki, HCL Tech, Yes Bank among 8 stocks that trended in Thursday’s trade

Exceptional income drives Biocon Q4 net up 79 % at Rs 361 crore

Biotechnology major Biocon today reported 79 per cent jump in consolidated net profit at Rs360.9 crore for the fourth quarter ended March 31, 2016, on the back of exceptional income and robust sales.

Exceptional income drives Biocon Q4 net up 79 % at Rs 361 crore

Biocon Q4 net profit jumps 79 pc to Rs 361 cr on higher sales, exceptional income

Biotechnology firm Biocon reported a 79.1 per cent increase in its net profit at Rs 360.9 crore for the fourth quarter ended March on top of higher sales and exceptional income.

Biocon Q4 net profit jumps 79 pc to Rs 361 cr on higher sales, exceptional income

Biocon Inc recalls 5,505 bottles of Simvastatin tablets in US

Biocon Inc, part of biotechnology major Biocon, is recalling in the US 5,505 bottles of cholesterol lowering Simvastatin tablets for being sub-potent, according to the USFDA.

Biocon Inc recalls 5,505 bottles of Simvastatin tablets in US

In a first, Biocon insulin gets Japan nod

Bio-pharma major Biocon on Monday became the first Indian company to receive regulatory approval for a biosimilar insulin in Japan.

Biocon’s Insulin Glargine receives regulatory approval in Japan

The product is ready to be launched in Q1 FY17

Biocon in co-development and commercialisation agreement with Lab PiSA

The collaboration is part of Biocon’s strategy to address the large demand for generic rh-insulin in the US

Govt paying mere ‘lip service’ to manufacturing sector: Kiran Mazumdar-Shaw

Labelling government's thrust on manufacturing sector as mere "lip service", Biocon chief Kiran Mazumdar-Shaw has said that ease of doing business in India has not improved...

Govt paying mere ‘lip service’ to manufacturing sector: Kiran Mazumdar-Shaw

Biocon receives first generic formulation approval in EU

The approval will enable the company to address $1.2 billion opportunity, starting FY17 Biocon has received European approvals for its Rosuvastatin Calcium 5 mg, 10 mg, 20 mg and 40 mg tablets, a generic equivalent of Crestor

Biocon Q3 net up 13% at Rs 103 crore

Biotechnology major Biocon has reported 13.31 per cent rise in consolidated net profit of Rs 103 crore for the third quarter ended December 31, 2015-16.

Biocon Q3 net up 13% at Rs 103 crore
Advertisement
Income Tax Calculator, Budget 2019, How to Calculate Income Tax

 

Stock Market

 

 

Advertisement

Focal Point

Advertisement

TRENDING NOW

BUDGET 2019

Related Articles

Switch to Hindi Edition